Farmers & Merchants Investments Inc. Has $39 Million Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Farmers & Merchants Investments Inc. lowered its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 2.0% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 47,223 shares of the company's stock after selling 970 shares during the period. Eli Lilly and Company accounts for approximately 1.2% of Farmers & Merchants Investments Inc.'s holdings, making the stock its 15th biggest holding. Farmers & Merchants Investments Inc.'s holdings in Eli Lilly and Company were worth $39,002,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of the business. Mascagni Wealth Management Inc. purchased a new position in Eli Lilly and Company in the 4th quarter worth about $43,000. FPC Investment Advisory Inc. grew its stake in shares of Eli Lilly and Company by 358.3% during the 4th quarter. FPC Investment Advisory Inc. now owns 55 shares of the company's stock valued at $45,000 after acquiring an additional 43 shares during the period. Prudent Man Investment Management Inc. bought a new position in shares of Eli Lilly and Company during the 4th quarter valued at approximately $48,000. Capital A Wealth Management LLC bought a new position in shares of Eli Lilly and Company during the 4th quarter valued at approximately $63,000. Finally, Bellwether Advisors LLC bought a new position in Eli Lilly and Company in the 4th quarter worth approximately $66,000. Institutional investors own 82.53% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the company. The Goldman Sachs Group upgraded Eli Lilly and Company from a "neutral" rating to a "buy" rating and lowered their target price for the company from $892.00 to $888.00 in a research report on Tuesday, April 8th. Cantor Fitzgerald assumed coverage on Eli Lilly and Company in a report on Tuesday, April 22nd. They set an "overweight" rating and a $975.00 price target on the stock. UBS Group reduced their target price on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating on the stock in a research note on Friday, May 2nd. Morgan Stanley restated an "overweight" rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. Finally, Erste Group Bank downgraded Eli Lilly and Company from a "buy" rating to a "hold" rating in a research report on Thursday, June 5th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and eighteen have issued a buy rating to the company. According to data from MarketBeat.com, Eli Lilly and Company has a consensus rating of "Moderate Buy" and a consensus price target of $1,011.37.

Eli Lilly and Company Stock Performance

Shares of LLY traded up $6.53 during midday trading on Friday, hitting $818.56. 2,753,537 shares of the stock traded hands, compared to its average volume of 3,651,766. Eli Lilly and Company has a 1-year low of $677.09 and a 1-year high of $972.53. The firm has a market capitalization of $775.78 billion, a PE ratio of 69.90, a price-to-earnings-growth ratio of 1.40 and a beta of 0.41. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. The business's 50 day moving average price is $775.43 and its two-hundred day moving average price is $801.50.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing the consensus estimate of $4.64 by ($1.30). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. The company had revenue of $12.73 billion during the quarter, compared to analyst estimates of $12.77 billion. During the same period in the previous year, the company earned $2.58 EPS. The business's revenue for the quarter was up 45.2% compared to the same quarter last year. Equities research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Friday, May 16th were given a $1.50 dividend. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.73%. The ex-dividend date was Friday, May 16th. Eli Lilly and Company's dividend payout ratio (DPR) is 48.82%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.